---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-23-000020"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:44:22.023998+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pacira Q1 total revenue $160.3M; net loss $19.5M; EXPAREL sales $130.4M

## Summary
- Total revenues $160.3M vs $158.0M in Q1 2022, up 1.5%; GAAP net loss $0.43/share vs net income $0.15/share.
- EXPAREL net product sales $130.4M, avg daily volumes up 6%, offset by 340B pricing; ZILRETTA $24.3M; iovera° $4.0M.
- Adjusted EBITDA $41.9M vs $53.8M in Q1 2022; non-GAAP net income $24.3M ($0.53 diluted share).
- FDA accepted sNDA for EXPAREL lower-extremity nerve blocks; PDUFA date Nov 13, 2023.
- Repaid $287.5M Term Loan B using $150M new Term Loan A and cash; appointed Christopher Young Chief Manufacturing Officer.

## SEC filing metadata
- accession: 0001396814-23-000020
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000020/0001396814-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000020/pcrx-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-23-000020
- JSON: https://secwatch.observer/filing/0001396814-23-000020.json
- Plain text: https://secwatch.observer/filing/0001396814-23-000020.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported the first quarter of 2023 results: revenue $160.3 million, net income $19.5 million, EPS $0.43 per share (basic and diluted). Guidance reaffirmed.
  - Period: the first quarter of 2023
  - Revenue: $160.3 million
  - Net income: $19.5 million
  - EPS: $0.43 per share (basic and diluted)
  - Guidance: reaffirmed
  - Result: reported results
  source text: pain management and regenerative health solutions, today reported financial results for the first quarter of 2023. First Quarter 2023 Financial Highlights • Total revenues of $160.3 million • Net product sales of $130.4 million for EXPAREL, $24.3 million for ZILRETTA, and $4.0 million for iovera° • Net loss of $19.5 million, or $0.43 per share (basic and diluted) •
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000020/0001396814-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.